<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2020.01536</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of Exercise Training on Exercise Tolerance and Level of Oxidative Stress for Head and Neck Cancer Patients Following Chemotherapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Yen</surname> <given-names>Chia-Jui</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hung</surname> <given-names>Ching-Hsia</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x2020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tsai</surname> <given-names>Wei-Ming</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cheng</surname> <given-names>Hui-Ching</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yang</surname> <given-names>Hsin-Lun</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lu</surname> <given-names>Yan-Jhen</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Tsai</surname> <given-names>Kun-Ling</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/139249/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Division of Hematology and Oncology, Department of Internal Medicine, Graduate Institute of Clinical Medicine, National Cheng Kung University Hospital</institution>, <addr-line>Tainan</addr-line>, <country>Taiwan</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Physical Therapy, College of Medicine, National Cheng Kung University</institution>, <addr-line>Tainan</addr-line>, <country>Taiwan</country></aff>
<aff id="aff3"><sup>3</sup><institution>Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University</institution>, <addr-line>Tainan</addr-line>, <country>Taiwan</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Shin-Da Lee, China Medical University, Taiwan</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Cheng-Chia Yu, Chung Shan Medical University, Taiwan; Mohd Ali Katijjahbe, National University of Malaysia, Malaysia</p></fn>
<corresp id="c001">&#x002A;Correspondence: Kun-Ling Tsai, <email>kunlingtsai@mail.ncku.edu.tw</email>; <email>kunlingtsai@gmail.com</email></corresp>
<fn fn-type="other" id="fn002"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
<fn fn-type="other" id="fn004"><p>This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>10</volume>
<elocation-id>1536</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>06</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>07</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2020 Yen, Hung, Tsai, Cheng, Yang, Lu and Tsai.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Yen, Hung, Tsai, Cheng, Yang, Lu and Tsai</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<sec><title>Background</title><p>Chemotherapy decreases fitness performance via repression of cardiopulmonary function and oxidative stress. This study was designed to investigate whether exercise intervention could improve exercises capacity and reduce systemic oxidative stress in patients with head and neck (H&#x0026;N) cancer receiving chemotherapy.</p></sec>
<sec><title>Methods</title><p>This is a single-center study. Forty-two H&#x0026;N cancer patients who were undergoing chemotherapy were recruited in this study. An 8-week exercise intervention was performed by conducting the combination of aerobic and resistance exercise 3 days a week. The exercise training was conducted by a physiotherapist. The exercise capacity and exercise responses were measured from blood pressure (BP) and heart rate (HR). Oxidative stress markers from human plasma, such as total antioxidant capacity, 8-hydroxy-2&#x2032;-deoxyguanosine, malondialdehyde, and carbonyl content, were tested by activity kits.</p></sec>
<sec><title>Results</title><p>We provide compelling evidence that exercise training ameliorated exercise responses and increased exercise capacity by repressing resting BP and increasing 1- and 3-min BP recovery. We also found the resting HR was reduced, and the 1- and 3-min HR recovery was increased after exercise training. In addition, the rating of perceived exertion after the peak exercise was reduced after exercise intervention. We also found that exercise training repressed oxidative stress markers by elevation of total antioxidant capacity and suppression of 8-OHd and carbonyl content in plasma.</p></sec>
<sec><title>Discussion</title><p>We clearly demonstrate that exercise can promote exercise capacity and reduce oxidative stress in H&#x0026;N cancer patients receiving chemotherapy, which might guide new therapeutic approaches for cancer patients, especially those undergoing chemotherapy.</p></sec>
</abstract>
<kwd-group>
<kwd>head and neck cancer</kwd>
<kwd>exercise</kwd>
<kwd>exercise capacity</kwd>
<kwd>oxidative stress</kwd>
<kwd>chemotherapy</kwd>
</kwd-group><counts>
<fig-count count="1"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="37"/>
<page-count count="8"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Introduction</title>
<p>Head and neck (H&#x0026;N) cancers are gaged to be one of the most prevalent cancer types in this world (<xref ref-type="bibr" rid="B1">1</xref>). During the past decades, chemotherapy of H&#x0026;N cancer has undergone extensive testing in clinical trials, and important milestones have been achieved in several fields (<xref ref-type="bibr" rid="B2">2</xref>). Several chemotherapy drugs have been used in patients with H&#x0026;N cancer such as cisplatin or carboplatin. Cisplatin given at a concentration of 80&#x2013;120 mg/m<sup>2</sup> per month causes an overall treatment response rate of 28% (<xref ref-type="bibr" rid="B3">3</xref>). Although chemotherapy has improved survival markedly in H&#x0026;N cancer patients, a large percentage of cases with H&#x0026;N severely suffered from side effects such as decreased quality of life (QoL) and physical function, neuropathy, and fatigue during treatment (<xref ref-type="bibr" rid="B4">4</xref>). A previous study suggested that chemotherapy not only attacks cancer cells but also influences normal tissue to cause systemic organ injury. One of the most critical problems is reduced fitness performance caused by the cardiopulmonary function during chemotherapy, which leads to low QoL (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Persuasive studies have concluded that cancer patients receiving chemotherapy have significant impairments in cardiorespiratory fitness and exercise capacity. The reduced physical activity suppresses cardiorespiratory fitness (<xref ref-type="bibr" rid="B6">6</xref>). Chemotherapy has been shown to cause muscle weakness and muscle atrophy, which reduces the diffusion transport of blood in skeletal muscle and thus results in decreased cardiorespiratory fitness (<xref ref-type="bibr" rid="B7">7</xref>). Moreover, deterioration of cardiac function is another important cause of reduced cardiorespiratory fitness. Chemotherapy can induce significant dysfunction in left ventricle, eventually leading to a reduction of cardiac contractility and cardiac output (<xref ref-type="bibr" rid="B8">8</xref>). In addition, the increased apoptosis and oxidative stress in cardiomyocytes are critical mechanisms in chemotherapy-induced cardiotoxicity (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>A previous study reported increased formation of serum oxidative markers in patients with H&#x0026;N cancer (<xref ref-type="bibr" rid="B10">10</xref>). In addition, chemotherapy has been reported to increase oxidative stress in cancer patients. This is obviously due to increased lipid peroxidation products that reduce free radical&#x2013;scavenging capacity and antioxidant activity during chemotherapy (<xref ref-type="bibr" rid="B11">11</xref>). Oxidative stress has been suggested to modulate cellular signals that are required for chemotherapy to effectively destroy cancer cells (<xref ref-type="bibr" rid="B12">12</xref>). The systemic antioxidant capacity is suppressed, and the protein oxidation is elevated in cancer patients undergoing chemotherapy; therefore, it may be probable that oxidative stress contributes to cardiorespiratory fitness reduction in cancer subjects after cancer management (<xref ref-type="bibr" rid="B13">13</xref>). Antioxidants supplements can reduce or prevent side effects caused by chemotherapy, but they may diminish the clinical effectiveness of chemotherapeutic treatments (<xref ref-type="bibr" rid="B14">14</xref>). Thus, to find effective interventions rather than antioxidants supplements for cancer patients is important.</p>
<p>Exercise is very helpful for the recovery from cancer treatments. Moderate-intensity exercise training can improve cancer patients&#x2019; mental health as compared to non-exercise subjects (<xref ref-type="bibr" rid="B15">15</xref>). In addition, a previous study has also suggested that appropriate exercise can improve the discomforts caused by chemotherapy in cancer patients. Mohamady et al. (<xref ref-type="bibr" rid="B16">16</xref>) reported that 12 weeks of moderate-intensity aerobic exercise enriched hemoglobin and erythrocytes in the circulatory system, thereby improving the clinical symptoms of anemia. However, whether exercise training can reduce oxidative stress in H&#x0026;N cancer patients receiving chemotherapy is still unclear. The primary aim of this present study was to investigate the effect of 8 weeks&#x2019; combinative exercise training on cardiorespiratory fitness in patients receiving chemotherapy. We hypothesized that exercise intervention ameliorates exercise responses and exercise capacity in cancer subjects undergoing chemotherapy. The secondary aim was to examine changes in oxidative stress marker in patient plasma. The hypothesis was that exercise training reduces oxidative stress markers in cancer subjects undergoing chemotherapy.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>This single-center study was conducted between September 2016 and December 2017 as a single-arm study. The National Cheng Kung University and National Cheng Kung University Hospital were responsible for the integrity and conduct of this study. This study was approved by the ethical committee of National Cheng Kung University Hospital Institutional Review Board, Tainan, Taiwan (B-ER-105-102), and this trial was registered in Thai Clinical Trials Registry (TCTR20171211001). After explaining all the experimental procedures in detail, each case provided written consent to join in the study.</p>
<sec id="S2.SS1">
<title>Subjects</title>
<p>Head and neck cancer patients were recruited from the Department of Hematology and Oncology at the National Cheng Kung University Hospital, Tainan, Taiwan. The patient sample size was referred by previous cancer exercise reports (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). The characteristics of the studied population are presented in <xref ref-type="table" rid="T1">Table 1</xref>. The inclusion criteria included (1) age 20 years or older with H&#x0026;N cancer; (2) H&#x0026;N cancer diagnosed by pathology, cytology, or imaging; (3) no serious complications; (4) no brain tumor metastasis; and (5) no history of mental illness. The exclusion criteria included (1) those who could not sign the consent, (2) neurological disorders (e.g., stroke), (3) pregnant or lactating women, (4) severe psychiatric disorders (e.g., bipolar disorder and schizophrenia), (5) musculoskeletal disorders that limited mobility (e.g., myopathy, amputation), (6) severe organ failure, and (7) clinically determined to have a survival rate of less than 3 months.</p>
<table-wrap position="float" id="T1">
<label>TABLE 1</label>
<caption><p>Basic characteristics of subjects.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left">Basic characteristics</td>
<td valign="top" align="center">Exercise group (<italic>N</italic> = 30)</td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Gender</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Female</td>
<td valign="top" align="center">7</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Male</td>
<td valign="top" align="center">23</td>
</tr>
<tr>
<td valign="top" align="left">Risk factor</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Smoke</td>
<td valign="top" align="center">15</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Drink</td>
<td valign="top" align="center">20</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Chew the betel nuts</td>
<td valign="top" align="center">13</td>
</tr>
<tr>
<td valign="top" align="left">Age (years)</td>
<td valign="top" align="center">56 &#x00B1; 12.3</td>
</tr>
<tr>
<td valign="top" align="left">Height (m)</td>
<td valign="top" align="center">1.6 &#x00B1; 0.7</td>
</tr>
<tr>
<td valign="top" align="left">Body weight (kg)</td>
<td valign="top" align="center">64.6 &#x00B1; 11.2</td>
</tr>
<tr>
<td valign="top" align="left">Chemotherapy drugs</td>
<td/>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Cisplatin</td>
<td valign="top" align="center">22</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Gemcitabine</td>
<td valign="top" align="center">1</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;Medroxyprogesterone</td>
<td valign="top" align="center">7</td>
</tr>
</tbody>
</table></table-wrap>
</sec>
<sec id="S2.SS2">
<title>Exercise Intervention</title>
<p>The subjects undergoing chemotherapy were arranged to receive 8 weeks of exercise training. Aerobic exercise and resistance exercise were included in the exercise program for patients. The participants were asked to perform exercise training 3 days per week in the gym in the National Cheng Kung University supervised by a physiotherapist. The training intensity was based on the American College of Sports Medicine&#x2019;s cancer patient guidelines: using moderate-intensity exercise training, with the intensity of the maximum heart rate (HR) ranging between 60 and 70%, where the maximum HR calculation formula is usually 220 &#x2212; age (<xref ref-type="bibr" rid="B19">19</xref>). Forty to fifty minutes of training time included a 5-min warm-up, aerobic exercise training for 30 min, and a 5-min cool-down. In addition, the TheraBand resistance band was used for resistance exercise in this study. Resistance exercise was performed by TheraBand at the intensity of the rating of perceived exertion (RPE) scale from &#x201C;somewhat heavy&#x201D; to &#x201C;heavy.&#x201D; Each exercise consists of 10 to 12 repetitions for one set, three sets per training. Both upper and lower extremities were trained.</p>
</sec>
<sec id="S2.SS3">
<title>Primary Outcome Measure&#x2013;Exercise Responses</title>
<p>The cardiovascular physiological parameters, including blood pressure (BP), HR, Sp<sc>O</sc><sub>2</sub>, and RPE, were measured in this study. Before and after exercise training, subjects were asked to perform an exercise to test the maximal exercise capacity and exercise responses. From the first day of recruitment to the last day of exercise training, the parameters in 1 and 3 min of recovery time were recorded after exercise testing.</p>
</sec>
<sec id="S2.SS4">
<title>Secondary Outcome Measures&#x2013;Measurement of Oxidative Stress</title>
<p>Human plasma was isolated from total blood collected from the first day of recruitment to the last day of exercise training. Total antioxidant capacity, 8-hydroxy-2&#x2032;-deoxyguanosine (8-OHdG), and carbonyl levels were measured using commercial kits (ab65329, ab201734, and ab126287; Abcam) according to the manufacturer&#x2019;s instructions. The malondialdehyde (MDA) level was determined by a commercial kit (MAK085, Sigma) according to the manufacturer&#x2019;s instructions.</p>
</sec>
</sec>
<sec id="S3">
<title>Statistics</title>
<p>Data were expressed as mean &#x00B1; standard deviations for all variables. No adjustment was made for analysis. The paired <italic>t</italic>-test was used to measure the differences in the mean values of the parameters between preintervention and postintervention. Statistical significance was set at <italic>p</italic> &#x003C; 0.05. All analyses were done using SPSS version 22.0 (SPSS Inc., Chicago, IL, United States).</p>
</sec>
<sec id="S4">
<title>Results</title>
<sec id="S4.SS1">
<title>Participant Flow and Recruitment</title>
<p>A total of 42 patients were screened in this study, 30 subjects were enrolled, and 12 subjects were excluded including 5 subjects who withdrew from participation, 2 subjects with changed treatment plan, 2 subjects with severe metastasis, and 3 subjects lost to follow-up (<xref ref-type="fig" rid="F1">Figure 1</xref>). All participants completed 8 weeks&#x2019; exercise training and data collection.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Flow of participants through the trial.</p></caption>
<graphic xlink:href="fonc-10-01536-g001.tif"/>
</fig>
</sec>
<sec id="S4.SS2">
<title>Demographic Data</title>
<p>Participant demographics are shown in <xref ref-type="table" rid="T1">Table 1</xref>. A total of 23 of 30 participants were male; a total of 7 of 30 participants were female. The mean &#x00B1; SD age of the total subjects was 56 &#x00B1; 12.3 years. The mean &#x00B1; SD height of the total subjects was 1.6 &#x00B1; 0.7 m, and the mean body weight of the total subjects was 64.4 &#x00B1; 11.2 kg. All participants had undergone chemotherapy (22 subjects were treated with cisplatin, 1 case was treated with gemcitabine, 7 subjects were treated with medroxyprogesterone).</p>
</sec>
<sec id="S4.SS3">
<title>Outcomes</title>
<sec id="S4.SS3.SSS1">
<title>Blood Pressure</title>
<p>As shown in <xref ref-type="table" rid="T2">Table 2</xref>, the results from BP revealed that resting systolic BP (SBP) and dystolic BP (DBP) are lower after exercise training (SBP pretraining 111 &#x00B1; 18.7, SBP posttraining 106.8 &#x00B1; 12.1; DBP pretraining 69.6 &#x00B1; 12.6, SBP posttraining 64 &#x00B1; 10.6; all <italic>p</italic> &#x003C; 0.05). There was no significant difference in both SBP and DBP in peak exercise before and after exercise training. In addition, exercise training increased 1- and 3-min BP recovery in DBP (<italic>p</italic> &#x003C; 0.05) and increased 3-min BP recovery in SBP (<italic>p</italic> &#x003C; 0.05) (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
<table-wrap position="float" id="T2">
<label>TABLE 2</label>
<caption><p>Blood pressure, heart rate, oxygen saturation, and rate of perceived exertion at pretraining/posttraining.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="center" colspan="2">Subjects (<italic>N</italic> = 30)<hr/></td>
</tr>
<tr>
<td/>
<td valign="top" align="center">Pretraining</td>
<td valign="top" align="center">Posttraining</td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left"><bold>Blood pressure</bold></td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Rest</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">&#x2003;SBP (mmHg)</td>
<td valign="top" align="center">111 &#x00B1; 18.7</td>
<td valign="top" align="center">106.8 &#x00B1; 12.1&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;DBP (mmHg)</td>
<td valign="top" align="center">69.6 &#x00B1; 12.6</td>
<td valign="top" align="center">64 &#x00B1; 10.6&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">Peak</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">&#x2003;SBP (mmHg)</td>
<td valign="top" align="center">156.9 &#x00B1; 24.3</td>
<td valign="top" align="center">157.6 &#x00B1; 22.7</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;DBP (mmHg)</td>
<td valign="top" align="center">82.7 &#x00B1; 16.4</td>
<td valign="top" align="center">83.7 &#x00B1; 13.8</td>
</tr>
<tr>
<td valign="top" align="left">1-min Recovery</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">&#x2003;SBP (mmHg)</td>
<td valign="top" align="center">111.8 &#x00B1; 22</td>
<td valign="top" align="center">108.9 &#x00B1; 13.2</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;DBP (mmHg)</td>
<td valign="top" align="center">70.2 &#x00B1; 14.6</td>
<td valign="top" align="center">66.4 &#x00B1; 11.3&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">3-min Recovery</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">&#x2003;SBP (mmHg)</td>
<td valign="top" align="center">105.1 &#x00B1; 15.9</td>
<td valign="top" align="center">100.2 &#x00B1; 11.9&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">&#x2003;DBP (mmHg)</td>
<td valign="top" align="center">66.8 &#x00B1; 12.9</td>
<td valign="top" align="center">60.9 &#x00B1; 10.6&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left"><bold>Heart rate</bold></td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Rest HR (beats)</td>
<td valign="top" align="center">85.2 &#x00B1; 12.1</td>
<td valign="top" align="center">76.4 &#x00B1; 10.2&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">Peak HR (beats)</td>
<td valign="top" align="center">131 &#x00B1; 15.8</td>
<td valign="top" align="center">132.5 &#x00B1; 14</td>
</tr>
<tr>
<td valign="top" align="left">Rest 1-min HR (beats)</td>
<td valign="top" align="center">99.3 &#x00B1; 13.3</td>
<td valign="top" align="center">93.6 &#x00B1; 12.1&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">Rest 3-min HR (beats)</td>
<td valign="top" align="center">94.8 &#x00B1; 12.1</td>
<td valign="top" align="center">85 &#x00B1; 13.2&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">Rest 1-min HRR (beats)</td>
<td valign="top" align="center">31.6 &#x00B1; 14.6</td>
<td valign="top" align="center">38.9 &#x00B1; 15.2&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">Rest 3-min HRR (beats)</td>
<td valign="top" align="center">36.2 &#x00B1; 14.6</td>
<td valign="top" align="center">47.5 &#x00B1; 16.4&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left"><bold>Oxygen saturation</bold></td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Rest Sp<sc>O</sc><sub>2</sub></td>
<td valign="top" align="center">97.8 &#x00B1; 1.3</td>
<td valign="top" align="center">97.9 &#x00B1; 1.1</td>
</tr>
<tr>
<td valign="top" align="left">Peak Sp<sc>O</sc><sub>2</sub></td>
<td valign="top" align="center">97 &#x00B1; 1.5</td>
<td valign="top" align="center">97.1 &#x00B1; 2.5</td>
</tr>
<tr>
<td valign="top" align="left">Rest 1-min Sp<sc>O</sc><sub>2</sub></td>
<td valign="top" align="center">97.2 &#x00B1; 1.4</td>
<td valign="top" align="center">97.4 &#x00B1; 1.4</td>
</tr>
<tr>
<td valign="top" align="left">Rest 3-min Sp<sc>O</sc><sub>2</sub></td>
<td valign="top" align="center">97 &#x00B1; 1.6</td>
<td valign="top" align="center">97.4 &#x00B1; 1.7</td>
</tr>
<tr>
<td valign="top" align="left"><bold>Rate of perceived exertion</bold></td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Rest RPE</td>
<td valign="top" align="center">10.8 &#x00B1; 0.4</td>
<td valign="top" align="center">10.8 &#x00B1; 0.4</td>
</tr>
<tr>
<td valign="top" align="left">Peak RPE</td>
<td valign="top" align="center">13.4 &#x00B1; 1.3</td>
<td valign="top" align="center">13.2 &#x00B1; 1.1</td>
</tr>
<tr>
<td valign="top" align="left">Rest 1-min RPE</td>
<td valign="top" align="center">11.2 &#x00B1; 0.7</td>
<td valign="top" align="center">10.9 &#x00B1; 0.5&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">Rest 3-min RPE</td>
<td valign="top" align="center">10.8 &#x00B1; 0.7</td>
<td valign="top" align="center">10.8 &#x00B1; 20.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib><italic>&#x002A;<italic>p</italic> &#x003C; 0.05 pretraining versus posttraining. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; HRR, heart rate recovery; Sp<sc>O</sc><sub>2</sub>, oxygen saturation; RPE, rate of perceived exertion.</italic></attrib>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S4.SS3.SSS2">
<title>Heart Rate</title>
<p>The results from HR indicated that resting HR is lower after exercise training (rest HR pretraining 85.2 &#x00B1; 12.1, rest HR posttraining 76.4 &#x00B1; 10.2; <italic>p</italic> &#x003C; 0.05). There was no significant difference in HR in peak exercise before and after exercise training. Moreover, exercise training reduced 1- and 3-min HR after peak exercise (1-min HR pretraining 99.3 &#x00B1; 13.3, 1-min HR posttraining 93.6 &#x00B1; 12.1; 3-min HR pretraining 94.8 &#x00B1; 12.1, 3-min HR posttraining 85 &#x00B1; 13.2; all <italic>p</italic> &#x003C; 0.05). A similar result had been found in HR recovery (HRR) data (all <italic>p</italic> &#x003C; 0.05).</p>
</sec>
<sec id="S4.SS3.SSS3">
<title>Oxygen Saturation</title>
<p>There was no significant difference in oxygen saturation in resting or peak exercise before and after exercise training.</p>
</sec>
<sec id="S4.SS3.SSS4">
<title>Rate of Perceived Exertion</title>
<p>There was no significant difference in RPE in resting or peak exercise before and after exercise training. However, exercise training reduced 1-min RPE after peak exercise (1-min RPE pretraining 11.2 &#x00B1; 0.7, 1-min RPE posttraining 10.9 &#x00B1; 0.5; <italic>p</italic> &#x003C; 0.05).</p>
</sec>
<sec id="S4.SS3.SSS5">
<title>Oxidative Stress Markers</title>
<p>We found that exercise training significantly increased total antioxidant capacity (pretraining 221.7 &#x00B1; 62.2, posttraining 443.7 &#x00B1; 72.1; <italic>p</italic> &#x003C; 0.05). Moreover, plasma levels of carbonyl content and 8-OHdG were decreased after exercise training (carbonyl content pretraining 10.1 &#x00B1; 2.6, carbonyl content posttraining 5.5 &#x00B1; 1.8; 8-OHdG pretraining 1031.3 &#x00B1; 43.8, 8-OHdG posttraining 761.3 &#x00B1; 66.3; all <italic>p</italic> &#x003C; 0.05). However, level of MDA was not changed in plasma (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap position="float" id="T3">
<label>TABLE 3</label>
<caption><p>The oxidative stress markers at pretraining/posttraining.</p></caption>
<table cellspacing="5" cellpadding="5" frame="hsides" rules="groups">
<thead>
<tr>
<td valign="top" align="left"></td>
<td valign="top" align="center" colspan="2">Subjects (<italic>N</italic> = 30)<hr/></td>
</tr>
<tr>
<td/>
<td valign="top" align="center">Pretraining</td>
<td valign="top" align="center">Posttraining</td>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Total antioxidant capacity (&#x03BC;M)</td>
<td valign="top" align="center">221.7 &#x00B1; 62.2</td>
<td valign="top" align="center">443.7 &#x00B1; 72.1&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">8-OHdG (ng/mL)</td>
<td valign="top" align="center">1031.3 &#x00B1; 43.8</td>
<td valign="top" align="center">761.3 &#x00B1; 66.3&#x002A;</td>
</tr>
<tr>
<td valign="top" align="left">MDA (nmol/mL)</td>
<td valign="top" align="center">4.7 &#x00B1; 0.8</td>
<td valign="top" align="center">3.8 &#x00B1; 1.3</td>
</tr>
<tr>
<td valign="top" align="left">Carbonyl content (nmol/mg protein)</td>
<td valign="top" align="center">10.1 &#x00B1; 2.6</td>
<td valign="top" align="center">5.5 &#x00B1; 1.8&#x002A;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<attrib><italic>&#x002A;<italic>p</italic> &#x003C; 0.05 pretraining versus posttraining. 8-OHdG, 8-hydroxy-2&#x2032;-deoxyguanosine; MDA, malondialdehyde.</italic></attrib>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
</sec>
<sec id="S5">
<title>Discussion</title>
<p>This is the first study to explore the effect of exercise training on cardiovascular physiological parameters and oxidative stress markers in H&#x0026;N cancer patients receiving chemotherapy. Here, we clearly demonstrated that exercise training ameliorated exercise responses by repression of resting HR and BP and promotion of HR and BP recovery. We also proved that exercise training mitigated decreased systemic oxidative stress in H&#x0026;N cancer patients receiving chemotherapy.</p>
<p>Chemotherapy drugs are extensively used to remedy patients with H&#x0026;N cancer. A previous report revealed that chemotherapy drugs not only attack cancer cells but also influence normal tissues to cause systemic organ injury. One of the most important issues is decreased QoL and reduced fitness performance resulting from repression of cardiopulmonary function (<xref ref-type="bibr" rid="B5">5</xref>). In addition, increased systemic oxidative stress is also considered to be a side effect of chemotherapy (<xref ref-type="bibr" rid="B20">20</xref>). In the present study, we demonstrated that exercise training not only improved exercise responses and exercise capacity but also mitigated systemic oxidative stress in H&#x0026;N cancer patients receiving chemotherapy.</p>
<p>High BP has been positively associated with the mortality rate in various cardiovascular diseases (<xref ref-type="bibr" rid="B21">21</xref>). Hypertension is one of the clinical side effects after chemotherapy treatments. Chemotherapy drugs impair vascular endothelial function and repressed nitric oxide (NO) synthesis, thereby causing vasoconstriction (<xref ref-type="bibr" rid="B22">22</xref>). In addition, a clinical trial reported that 144 cases who received chemotherapy developed elevated BP, with an incidence rate ranging from 8 to 67% (<xref ref-type="bibr" rid="B23">23</xref>). Notably, exercise training can effectively mitigate the incidence of cardiovascular disease by 30% and the incidence of mortality by 52% (<xref ref-type="bibr" rid="B24">24</xref>). Body vascular resistance can be reduced after exercise (<xref ref-type="bibr" rid="B25">25</xref>), which may result from that exercise decreases the levels of reactive blood oxygen species and thus lowers BP (<xref ref-type="bibr" rid="B26">26</xref>). In the present study, we found that exercise intervention reduced resting SBP and DBP and improved 1-min DBP recovery, 3-min SBP recovery, and 3-min DBP recovery, suggesting that exercise intervention has potential to ameliorate exercise responses in H&#x0026;N cancer patients receiving chemotherapy (<xref ref-type="table" rid="T2">Table 2</xref>). Results from this part indicated that exercise training ameliorates vessel adaptation in H&#x0026;N cancer patients receiving chemotherapy.</p>
<p>The HR response to exercise is reported to a complex interaction among many factors such as age, physical conditioning, and sympathetic system, as well as venous return (<xref ref-type="bibr" rid="B27">27</xref>). Previous investigation has reported a correlation between non-success to achieve a predicted HR and the prognosis of cardiovascular disease (<xref ref-type="bibr" rid="B28">28</xref>). Jones et al. (<xref ref-type="bibr" rid="B29">29</xref>) indicated that chemotherapy medications have deleterious influences on the autonomic nervous system and motive endocrine system alteration that in turn affect the cardiovascular function and sympathetic and parasympathetic interplays. Exercise intervention had been suggested to repress the activity of the sympathetic nervous system and promote vasodilatation, thereby reducing the resting HR (<xref ref-type="bibr" rid="B30">30</xref>). Exercise training increases exercise capacity with the elevated peak HR; in addition, previous studies have found that long-term endurance exercise training can reduce the &#x03B2;1-adrenergic receptor in the right atrium because the &#x03B2;1-adrenergic receptor can receive sympathetic information, whereas aerobic endurance training increases cardiac parasympathetic activity that suppresses sympathetic activity and leads to declines in HR (<xref ref-type="bibr" rid="B31">31</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>). In our study, we confirmed that exercise training decreased resting HR and increased 1-min HR and 3-min HRR in H&#x0026;N cancer patients receiving chemotherapy. Results from this part indicated that exercise training mends HR responses in H&#x0026;N cancer patients receiving chemotherapy, which might be through ameliorating the balance of sympathetic and parasympathetic interplays.</p>
<p>The chemotherapy-induced cardiotoxicity has been connected to several mechanisms, including elevated production of reactive oxygen species, increased lipid peroxidation, mitochondrial impairment, and elevation of Ca<sup>2++</sup> concentration leading to systemic oxidative stress (<xref ref-type="bibr" rid="B34">34</xref>). Besides, chemotherapy drugs have been suggested to be involved in the elevation of nitrosative stress by up-regulated formation of potent reactive nitrogen species, such as peroxynitrite, by the action of superoxide with NO (<xref ref-type="bibr" rid="B35">35</xref>). Expression of cardiac NO was found to be induced during the progression of chemotherapy-facilitated cardiomyopathy by increased expression level of inducible NO synthase (<xref ref-type="bibr" rid="B36">36</xref>). Elevated oxidative stress acts as a facilitator for the progression of inflammation, leading to dysfunction of cardiovascular system (<xref ref-type="bibr" rid="B36">36</xref>). Previous reports suggested that exercise is a useful intervention to prevent several risk factors of cardiovascular disease. For example, exercise intervention furnishes various positive effects on human endothelial function and maintains cardiovascular homeostasis by activation of antioxidative capacities (<xref ref-type="bibr" rid="B37">37</xref>). Our data show that exercise training increased total antioxidant capacity and reduced 8-OHdG and carbonyl content levels in H&#x0026;N cancer patients receiving chemotherapy, indicating that exercise may protect against cardiovascular dysfunction caused by chemotherapy repressing systemic oxidative stress.</p>
<p>Most approaches for cancer case involve chemotherapy that induces injuries to the patient&#x2019;s body. In addition, the systemic side effects may affect their daily life activities and reduce their QoL and exercise capacity. In our study, exercise training was shown to have beneficial effects on cardiovascular physiological responses exercise capacity in H&#x0026;N cancer cases receiving chemotherapy.</p>
</sec>
<sec id="S6">
<title>Conclusion</title>
<p>In summary, chemotherapy not only attacks cancer tissues but also influences normal tissues to cause systemic damages. One of the most critical causes in QoL repression is reduced fitness performance resulting from the impairment of cardiopulmonary function and exercise capacity. In addition, high oxidative stress has been involved in cardiotoxicity caused by chemotherapy. In this study, we clearly demonstrated that exercise training ameliorated exercise responses and increased exercise capacity in H&#x0026;N cancer patients receiving chemotherapy, which may be attributed to decreased systemic oxidative stress. Our data provide a well-distinguished pathway to guide new therapeutic approaches for treating patients receiving chemotherapy.</p>
</sec>
<sec id="S7">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.</p>
</sec>
<sec id="S8">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by the National Cheng Kung University. The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="S9">
<title>Author Contributions</title>
<p>C-JY, C-HH, W-MT, and K-LT participated in study design. H-CC participated in acquisition of data. H-LY, Y-JL, and K-LT participated in interpretation of data. C-JY, C-HH, and K-LT helped to draft the manuscript. C-HH and K-LT contributed to the conception and design of the study and final approval of the submitted version. All authors read and approved the final manuscript.</p>
</sec>
<sec id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This study was supported by Ministry of Science and Technology, Taiwan (MOST-106-2314-B-006 -023).</p>
</fn>
</fn-group>
<ack>
<p>We sincerely thank Clinical Medicine Research Center of National Cheng Kung University Hospital, Taiwan for providing the consulting services of manuscript editing and writing.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iglesias</surname> <given-names>DLC</given-names></name> <name><surname>Arrazubi</surname> <given-names>AV</given-names></name> <name><surname>Baste</surname> <given-names>RN</given-names></name> <name><surname>Carral</surname> <given-names>MA</given-names></name> <name><surname>Cirauqui</surname> <given-names>CB</given-names></name> <name><surname>Escobar</surname> <given-names>Y</given-names></name><etal/></person-group> <article-title>SEOM clinical guidelines for the treatment of head and neck cancer (2017).</article-title> <source><italic>Clin Transl Oncol.</italic></source> (<year>2018</year>) <volume>20</volume>:<fpage>75</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s12094-017-1776-1</pub-id> <pub-id pub-id-type="pmid">29159792</pub-id></citation></ref>
<ref id="B2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dimery</surname> <given-names>IW</given-names></name> <name><surname>Hong</surname> <given-names>WK.</given-names></name></person-group> <article-title>Overview of combined modality therapies for head and neck cancer.</article-title> <source><italic>J Natl Cancer Inst.</italic></source> (<year>1993</year>) <volume>85</volume>:<fpage>95</fpage>&#x2013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/85.2.95</pub-id> <pub-id pub-id-type="pmid">8418313</pub-id></citation></ref>
<ref id="B3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veronesi</surname> <given-names>A</given-names></name> <name><surname>Zagonel</surname> <given-names>V</given-names></name> <name><surname>Tirelli</surname> <given-names>U</given-names></name> <name><surname>Galligioni</surname> <given-names>E</given-names></name> <name><surname>Tumolo</surname> <given-names>S</given-names></name> <name><surname>Barzan</surname> <given-names>L</given-names></name><etal/></person-group> <article-title>High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study.</article-title> <source><italic>J Clin Oncol.</italic></source> (<year>1985</year>) <volume>3</volume>:<fpage>1105</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1200/jco.1985.3.8.1105</pub-id> <pub-id pub-id-type="pmid">4040550</pub-id></citation></ref>
<ref id="B4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalter</surname> <given-names>J</given-names></name> <name><surname>Kampshoff</surname> <given-names>CS</given-names></name> <name><surname>Chinapaw</surname> <given-names>MJ</given-names></name> <name><surname>Vanm</surname> <given-names>W</given-names></name> <name><surname>Galindo-Garre</surname> <given-names>F</given-names></name> <name><surname>Schep</surname> <given-names>G</given-names></name><etal/></person-group> <article-title>Mediators of exercise effects on hrqol in cancer survivors after chemotherapy.</article-title> <source><italic>Med Sci Sports Exerc.</italic></source> (<year>2016</year>) <volume>48</volume>:<fpage>1859</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1249/mss.0000000000000976</pub-id> <pub-id pub-id-type="pmid">27128668</pub-id></citation></ref>
<ref id="B5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname> <given-names>BA</given-names></name> <name><surname>Galvao</surname> <given-names>DA</given-names></name> <name><surname>Fatehee</surname> <given-names>N</given-names></name> <name><surname>Taaffe</surname> <given-names>DR</given-names></name> <name><surname>Spry</surname> <given-names>N</given-names></name> <name><surname>Joseph</surname> <given-names>D</given-names></name><etal/></person-group> <article-title>Maximal exercise testing of men with prostate cancer being treated with androgen deprivation therapy.</article-title> <source><italic>Med Sci Sports Exerc.</italic></source> (<year>2014</year>) <volume>46</volume>:<fpage>2210</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1249/mss.0000000000000353</pub-id> <pub-id pub-id-type="pmid">24694745</pub-id></citation></ref>
<ref id="B6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loewen</surname> <given-names>GM</given-names></name> <name><surname>Watson</surname> <given-names>D</given-names></name> <name><surname>Kohman</surname> <given-names>L</given-names></name> <name><surname>Herndon</surname> <given-names>JE</given-names> <suffix>II</suffix></name> <name><surname>Shennib</surname> <given-names>H</given-names></name> <name><surname>Kernstine</surname> <given-names>K</given-names></name><etal/></person-group> <article-title>Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.</article-title> <source><italic>J Thorac Oncol.</italic></source> (<year>2007</year>) <volume>2</volume>:<fpage>619</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1097/jto.0b013e318074bba7</pub-id> <pub-id pub-id-type="pmid">17607117</pub-id></citation></ref>
<ref id="B7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galvao</surname> <given-names>DA</given-names></name> <name><surname>Spry</surname> <given-names>NA</given-names></name> <name><surname>Taaffe</surname> <given-names>DR</given-names></name> <name><surname>Newton</surname> <given-names>RU</given-names></name> <name><surname>Stanley</surname> <given-names>J</given-names></name> <name><surname>Shannon</surname> <given-names>T</given-names></name><etal/></person-group> <article-title>Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.</article-title> <source><italic>BJU Int.</italic></source> (2008) <volume>102</volume>:<fpage>44</fpage>&#x2013;<lpage>7</lpage>.</citation></ref>
<ref id="B8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swain</surname> <given-names>SM</given-names></name> <name><surname>Whaley</surname> <given-names>FS</given-names></name> <name><surname>Ewer</surname> <given-names>MS.</given-names></name></person-group> <article-title>Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.</article-title> <source><italic>Cancer.</italic></source> (<year>2003</year>) <volume>97</volume>:<fpage>2869</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.11407</pub-id> <pub-id pub-id-type="pmid">12767102</pub-id></citation></ref>
<ref id="B9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Octavia</surname> <given-names>Y</given-names></name> <name><surname>Tocchetti</surname> <given-names>CG</given-names></name> <name><surname>Gabrielson</surname> <given-names>KL</given-names></name> <name><surname>Janssens</surname> <given-names>S</given-names></name> <name><surname>Crijns</surname> <given-names>HJ</given-names></name> <name><surname>Moens</surname> <given-names>AL.</given-names></name></person-group> <article-title>Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.</article-title> <source><italic>J Mol Cell Cardiol.</italic></source> (<year>2012</year>) <volume>52</volume>:<fpage>1213</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2012.03.006</pub-id> <pub-id pub-id-type="pmid">22465037</pub-id></citation></ref>
<ref id="B10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>AK</given-names></name> <name><surname>Pandey</surname> <given-names>P</given-names></name> <name><surname>Tewari</surname> <given-names>M</given-names></name> <name><surname>Pandey</surname> <given-names>HP</given-names></name> <name><surname>Gambhir</surname> <given-names>IS</given-names></name> <name><surname>Shukla</surname> <given-names>HS.</given-names></name></person-group> <article-title>Free radicals hasten head and neck cancer risk: a study of total oxidant, total antioxidant, DNA damage, and histological grade.</article-title> <source><italic>J Postgrad Med.</italic></source> (<year>2016</year>) <volume>62</volume>:<fpage>96</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.4103/0022-3859.180555</pub-id> <pub-id pub-id-type="pmid">27089108</pub-id></citation></ref>
<ref id="B11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname> <given-names>S</given-names></name> <name><surname>Subramaniam</surname> <given-names>S</given-names></name> <name><surname>Shyamala Devi</surname> <given-names>CS.</given-names></name></person-group> <article-title>Erythrocyte antioxidant enzyme activity in CMF treated breast cancer patients.</article-title> <source><italic>Cancer Biochem Biophys.</italic></source> (<year>1994</year>) <volume>14</volume>:<fpage>177</fpage>&#x2013;<lpage>82</lpage>.</citation></ref>
<ref id="B12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shacter</surname> <given-names>E</given-names></name> <name><surname>Williams</surname> <given-names>JA</given-names></name> <name><surname>Hinson</surname> <given-names>RM</given-names></name> <name><surname>Senturker</surname> <given-names>S</given-names></name> <name><surname>Lee</surname> <given-names>YJ.</given-names></name></person-group> <article-title>Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis.</article-title> <source><italic>Blood.</italic></source> (<year>2000</year>) <volume>96</volume>:<fpage>307</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1182/blood.v96.1.307.013k47_307_313</pub-id></citation></ref>
<ref id="B13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Repka</surname> <given-names>CP</given-names></name> <name><surname>Hayward</surname> <given-names>R.</given-names></name></person-group> <article-title>Oxidative stress and fitness changes in cancer patients after exercise training.</article-title> <source><italic>Med Sci Sports Exerc.</italic></source> (<year>2016</year>) <volume>48</volume>:<fpage>607</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1249/mss.0000000000000821</pub-id> <pub-id pub-id-type="pmid">26587845</pub-id></citation></ref>
<ref id="B14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>YJ</given-names></name> <name><surname>Shacter</surname> <given-names>E.</given-names></name></person-group> <article-title>Oxidative stress inhibits apoptosis in human lymphoma cells.</article-title> <source><italic>J Biol Chem.</italic></source> (<year>1999</year>) <volume>274</volume>:<fpage>19792</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.28.19792</pub-id> <pub-id pub-id-type="pmid">10391922</pub-id></citation></ref>
<ref id="B15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lesiuk</surname> <given-names>T.</given-names></name></person-group> <article-title>The effect of mindfulness-based music therapy on attention and mood in women receiving adjuvant chemotherapy for breast cancer: a pilot study.</article-title> <source><italic>Oncol Nurs Forum.</italic></source> (<year>2015</year>) <volume>42</volume>:<fpage>276</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1188/15.onf.276-282</pub-id></citation></ref>
<ref id="B16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohamady</surname> <given-names>HM</given-names></name> <name><surname>Elsisi</surname> <given-names>HF</given-names></name> <name><surname>Aneis</surname> <given-names>YM.</given-names></name></person-group> <article-title>Impact of moderate intensity aerobic exercise on chemotherapy-induced anemia in elderly women with breast cancer: a randomized controlled clinical trial.</article-title> <source><italic>J Adv Res.</italic></source> (<year>2017</year>) <volume>8</volume>:<fpage>7</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.jare.2016.10.005</pub-id> <pub-id pub-id-type="pmid">27872759</pub-id></citation></ref>
<ref id="B17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gehring</surname> <given-names>K</given-names></name> <name><surname>Kloek</surname> <given-names>CJ</given-names></name> <name><surname>Aaronson</surname> <given-names>NK</given-names></name> <name><surname>Janssen</surname> <given-names>KW</given-names></name> <name><surname>Jones</surname> <given-names>LW</given-names></name> <name><surname>Sitskoorn</surname> <given-names>MM</given-names></name><etal/></person-group> <article-title>Feasibility of a home-based exercise intervention with remote guidance for patients with stable grade II and III gliomas: a pilot randomized controlled trial.</article-title> <source><italic>Clin Rehabil.</italic></source> (<year>2018</year>) <volume>32</volume>:<fpage>352</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1177/0269215517728326</pub-id> <pub-id pub-id-type="pmid">28882061</pub-id></citation></ref>
<ref id="B18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>K</given-names></name> <name><surname>Gu</surname> <given-names>MO</given-names></name> <name><surname>Jung</surname> <given-names>JH</given-names></name> <name><surname>Hahm</surname> <given-names>JR</given-names></name> <name><surname>Kim</surname> <given-names>SK</given-names></name> <name><surname>Kim</surname> <given-names>JH</given-names></name><etal/></person-group> <article-title>Efficacy of a home-based exercise program after thyroidectomy for thyroid cancer patients.</article-title> <source><italic>Thyroid.</italic></source> (<year>2018</year>) <volume>28</volume>:<fpage>236</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1089/thy.2017.0277</pub-id> <pub-id pub-id-type="pmid">29258382</pub-id></citation></ref>
<ref id="B19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname> <given-names>CE</given-names></name> <name><surname>Blissmer</surname> <given-names>B</given-names></name> <name><surname>Deschenes</surname> <given-names>MR</given-names></name> <name><surname>Franklin</surname> <given-names>BA</given-names></name> <name><surname>Lamonte</surname> <given-names>MJ</given-names></name> <name><surname>Lee</surname> <given-names>IM</given-names></name><etal/></person-group> <article-title>American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise.</article-title> <source><italic>Med Sci Sports Exerc.</italic></source> (<year>2011</year>) <volume>43</volume>:<fpage>1334</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1249/mss.0b013e318213fefb</pub-id> <pub-id pub-id-type="pmid">21694556</pub-id></citation></ref>
<ref id="B20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>Z</given-names></name> <name><surname>Schumaker</surname> <given-names>LM</given-names></name> <name><surname>Egorin</surname> <given-names>MJ</given-names></name> <name><surname>Zuhowski</surname> <given-names>EG</given-names></name> <name><surname>Guo</surname> <given-names>Z</given-names></name> <name><surname>Cullen</surname> <given-names>KJ.</given-names></name></person-group> <article-title>Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis.</article-title> <source><italic>Clin Cancer Res.</italic></source> (<year>2006</year>) <volume>12</volume>:<fpage>5817</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-06-1037</pub-id> <pub-id pub-id-type="pmid">17020989</pub-id></citation></ref>
<ref id="B21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muntner</surname> <given-names>P</given-names></name> <name><surname>Krousel-Wood</surname> <given-names>M</given-names></name> <name><surname>Hyre</surname> <given-names>AD</given-names></name> <name><surname>Stanley</surname> <given-names>E</given-names></name> <name><surname>Cushman</surname> <given-names>WC</given-names></name> <name><surname>Cutler</surname> <given-names>JA</given-names></name><etal/></person-group> <article-title>Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines.</article-title> <source><italic>Hypertension.</italic></source> (<year>2009</year>) <volume>53</volume>:<fpage>617</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1161/hypertensionaha.108.120154</pub-id> <pub-id pub-id-type="pmid">19221214</pub-id></citation></ref>
<ref id="B22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname> <given-names>KL</given-names></name> <name><surname>Huang</surname> <given-names>PH</given-names></name> <name><surname>Kao</surname> <given-names>CL</given-names></name> <name><surname>Leu</surname> <given-names>HB</given-names></name> <name><surname>Cheng</surname> <given-names>YH</given-names></name> <name><surname>Liao</surname> <given-names>YW</given-names></name><etal/></person-group> <article-title>Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis.</article-title> <source><italic>Biochem Pharmacol.</italic></source> (<year>2014</year>) <volume>88</volume>:<fpage>189</fpage>&#x2013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2013.12.005</pub-id> <pub-id pub-id-type="pmid">24345330</pub-id></citation></ref>
<ref id="B23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gressett</surname> <given-names>SM</given-names></name> <name><surname>Shah</surname> <given-names>SR.</given-names></name></person-group> <article-title>Intricacies of bevacizumab-induced toxicities and their management.</article-title> <source><italic>Ann Pharmacother.</italic></source> (<year>2009</year>) <volume>43</volume>:<fpage>490</fpage>&#x2013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1l426</pub-id> <pub-id pub-id-type="pmid">19261963</pub-id></citation></ref>
<ref id="B24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname> <given-names>S</given-names></name> <name><surname>Yokoyama</surname> <given-names>N</given-names></name> <name><surname>Tamori</surname> <given-names>Y</given-names></name> <name><surname>Akutsu</surname> <given-names>K</given-names></name> <name><surname>Hashimoto</surname> <given-names>H</given-names></name> <name><surname>Takeshita</surname> <given-names>S.</given-names></name></person-group> <article-title>Patients with peripheral artery disease who complete 12-week supervised exercise training program show reduced cardiovascular mortality and morbidity.</article-title> <source><italic>Circulat J.</italic></source> (<year>2009</year>) <volume>73</volume>:<fpage>167</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1253/circj.cj-08-0141</pub-id> <pub-id pub-id-type="pmid">19039192</pub-id></citation></ref>
<ref id="B25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname> <given-names>SM</given-names></name> <name><surname>Solomon</surname> <given-names>SD.</given-names></name></person-group> <article-title>Influence of physical activity on hypertension and cardiac structure and function.</article-title> <source><italic>Curr Hypert Rep.</italic></source> (<year>2015</year>) <volume>17</volume>:<issue>77</issue>.</citation></ref>
<ref id="B26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haack</surname> <given-names>KK</given-names></name> <name><surname>Zucker</surname> <given-names>IH.</given-names></name></person-group> <article-title>Central mechanisms for exercise training-induced reduction in sympatho-excitation in chronic heart failure.</article-title> <source><italic>Autonom Neurosci.</italic></source> (<year>2015</year>) <volume>188</volume>:<fpage>44</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2014.10.015</pub-id> <pub-id pub-id-type="pmid">25458427</pub-id></citation></ref>
<ref id="B27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname> <given-names>HK</given-names></name> <name><surname>Froelicher</surname> <given-names>VF.</given-names></name></person-group> <article-title>Normal and abnormal heart rate responses to exercise.</article-title> <source><italic>Prog Cardiovasc Dis.</italic></source> (<year>1985</year>) <volume>27</volume>:<fpage>271</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/0033-0620(85)90010-6</pub-id></citation></ref>
<ref id="B28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellestad</surname> <given-names>MH</given-names></name> <name><surname>Wan</surname> <given-names>MK.</given-names></name></person-group> <article-title>Predictive implications of stress testing. Follow-up of 2700 subjects after maximum treadmill stress testing.</article-title> <source><italic>Circulation.</italic></source> (<year>1975</year>) <volume>51</volume>:<fpage>363</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/01.cir.51.2.363</pub-id></citation></ref>
<ref id="B29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>LW</given-names></name> <name><surname>Courneya</surname> <given-names>KS</given-names></name> <name><surname>Mackey</surname> <given-names>JR</given-names></name> <name><surname>Muss</surname> <given-names>HB</given-names></name> <name><surname>Pituskin</surname> <given-names>EN</given-names></name> <name><surname>Scott</surname> <given-names>JM</given-names></name><etal/></person-group> <article-title>Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.</article-title> <source><italic>J Clin Oncol.</italic></source> (<year>2012</year>) <volume>30</volume>:<fpage>2530</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2011.39.9014</pub-id> <pub-id pub-id-type="pmid">22614980</pub-id></citation></ref>
<ref id="B30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kingwell</surname> <given-names>BA.</given-names></name></person-group> <article-title>Nitric oxide as a metabolic regulator during exercise: effects of training in health and disease.</article-title> <source><italic>Clin Exp Pharmacol Physiol.</italic></source> (<year>2000</year>) <volume>27</volume>:<fpage>239</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1046/j.1440-1681.2000.03232.x</pub-id> <pub-id pub-id-type="pmid">10779120</pub-id></citation></ref>
<ref id="B31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname> <given-names>HK</given-names></name> <name><surname>White</surname> <given-names>FC</given-names></name> <name><surname>Brunton</surname> <given-names>LL</given-names></name> <name><surname>Longhurst</surname> <given-names>JC.</given-names></name></person-group> <article-title>Association of decreased myocardial beta-receptors and chronotropic response to isoproterenol and exercise in pigs following chronic dynamic exercise.</article-title> <source><italic>Circulat Res.</italic></source> (<year>1987</year>) <volume>60</volume>:<fpage>720</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1161/01.res.60.5.720</pub-id></citation></ref>
<ref id="B32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname> <given-names>JB</given-names></name> <name><surname>Banister</surname> <given-names>EW</given-names></name> <name><surname>Blaber</surname> <given-names>AP.</given-names></name></person-group> <article-title>Effect of endurance exercise on autonomic control of heart rate.</article-title> <source><italic>Sports Med (Auckland NZ).</italic></source> (<year>2003</year>) <volume>33</volume>:<fpage>33</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.2165/00007256-200333010-00003</pub-id> <pub-id pub-id-type="pmid">12477376</pub-id></citation></ref>
<ref id="B33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Angadi</surname> <given-names>SS</given-names></name> <name><surname>Jarrett</surname> <given-names>CL</given-names></name> <name><surname>Sherif</surname> <given-names>M</given-names></name> <name><surname>Gaesser</surname> <given-names>GA</given-names></name> <name><surname>Mookadam</surname> <given-names>F.</given-names></name></person-group> <article-title>The effect of exercise training on biventricular myocardial strain in heart failure with preserved ejection fraction.</article-title> <source><italic>ESC Heart Fail.</italic></source> (<year>2017</year>) <volume>4</volume>:<fpage>356</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/ehf2.12149</pub-id> <pub-id pub-id-type="pmid">28772048</pub-id></citation></ref>
<ref id="B34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludke</surname> <given-names>AR</given-names></name> <name><surname>Al-Shudiefat</surname> <given-names>AA</given-names></name> <name><surname>Dhingra</surname> <given-names>S</given-names></name> <name><surname>Jassal</surname> <given-names>DS</given-names></name> <name><surname>Singal</surname> <given-names>PK.</given-names></name></person-group> <article-title>A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity.</article-title> <source><italic>Can J Physiol Pharmacol.</italic></source> (<year>2009</year>) <volume>87</volume>:<fpage>756</fpage>&#x2013;<lpage>63</lpage>.</citation></ref>
<ref id="B35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname> <given-names>P</given-names></name> <name><surname>Rajesh</surname> <given-names>M</given-names></name> <name><surname>Batkai</surname> <given-names>S</given-names></name> <name><surname>Kashiwaya</surname> <given-names>Y</given-names></name> <name><surname>Hasko</surname> <given-names>G</given-names></name> <name><surname>Liaudet</surname> <given-names>L</given-names></name><etal/></person-group> <article-title>Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro.</article-title> <source><italic>Am J Physiol Heart Circ Physiol.</italic></source> (<year>2009</year>) <volume>296</volume>:<fpage>H1466</fpage>&#x2013;<lpage>83</lpage>.</citation></ref>
<ref id="B36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>S</given-names></name> <name><surname>Gupta</surname> <given-names>AK.</given-names></name></person-group> <article-title>Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies.</article-title> <source><italic>Cancer Chemother Pharmacol.</italic></source> (<year>2011</year>) <volume>67</volume>:<fpage>1211</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-011-1654-4</pub-id> <pub-id pub-id-type="pmid">21544630</pub-id></citation></ref>
<ref id="B37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>Y</given-names></name> <name><surname>Booth</surname> <given-names>FW</given-names></name> <name><surname>Lee</surname> <given-names>S</given-names></name> <name><surname>Laye</surname> <given-names>MJ</given-names></name> <name><surname>Zhang</surname> <given-names>C.</given-names></name></person-group> <article-title>Physical activity opposes coronary vascular dysfunction induced during high fat feeding in mice.</article-title> <source><italic>J Physiol.</italic></source> (<year>2012</year>) <volume>590</volume>:<fpage>4255</fpage>&#x2013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2012.234856</pub-id> <pub-id pub-id-type="pmid">22674721</pub-id></citation></ref>
</ref-list></back>
</article>
